The Importance of Suppressing Pathological Periostin Splicing Variants with Exon 17 in Both Stroma and Cancer
Cells · 2024
DOI: 10.3390/cells13171410 ↗Kurz gefasst
Fachartikel in der Zeitschrift Cells, 2024. Verfasst von Kana Shibata und 10 weiteren Autor:innen. Beteiligte Einrichtung: Department of Advanced Molecular Therapy, Graduate School of Medicine/Faculty of Medicine, Osaka University, Suita 565-0871, Japan. Hauptthemen laut MEDLINE: Cell Adhesion Molecules, Exons, Stromal Cells. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Grants in Aid for Scientific Research, START Project of the Ministry of Education, Culture, Sports, Science and Technology, JSPS KAKENHI.
Abstract (Originalsprache)
Background
Periostin (POSTN) is a type of matrix protein that functions by binding to other matrix proteins, cell surface receptors, or other molecules, such as cytokines and proteases. POSTN has four major splicing variants (PN1–4), which are primarily expressed in fibroblasts and cancer. We have reported that we should inhibit pathological POSTN (PN1–3), but not physiological POSTN (PN4). In particular, pathological POSTN with exon 17 is present in both stroma and cancer, but it is unclear whether the stroma or cancer pathological POSTN should be suppressed. Methods and Results: We transplanted 4T1 cells (breast cancer) secreting POSTN with exon 17 into 17KO mice lacking POSTN exon 17 to suppress stromal POSTN with exon 17. The results show that 17KO mice had smaller primary tumors and fewer metastases. Furthermore, to suppress cancer POSTN with exon 17, 4T1 cells transfected with POSTN exon 17 skipping oligo or control oligo were transplanted from the tail vein into the lungs. The results show that POSTN exon 17 skipping oligo significantly suppressed lung metastasis.
Conclusions
These findings suggest that it is important to suppress POSTN exon 17 in both stroma and cancer. Antibody targeting POSTN exon 17 may be a therapeutic candidate for breast cancer.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Advanced Molecular Therapy, Graduate School of Medicine/Faculty of Medicine, Osaka University, Suita 565-0871, Japan.
- Department of Clinical Gene Therapy, Graduate School of Medicine/Faculty of Medicine, Osaka University, Suita 565-0871, Japan.
- Department of Breast and Endocrine Surgery, Graduate School of Medicine/Faculty of Medicine, Osaka University, Suita 565-0871, Japan.
- Department of Geriatric and General Medicine, Graduate School of Medicine/Faculty of Medicine, Osaka University, Suita 565-0871, Japan.
- Graduate School of Dentistry (Oral and Maxillofacial Surgery), Osaka Dental University, Hirakata 573-1121, Japan.
ORCID-Profile: Fumihiro Sanada, Yoshiaki Taniyama
Förderung
- Grants in Aid for Scientific Research
- START Project of the Ministry of Education, Culture, Sports, Science and Technology
- JSPS KAKENHI
- Japan Agency for Medical Research and Development
- G7 Foundation
Zitieren
APA
Shibata, K., Koibuchi, N., Sanada, F., Katsuragi, N., Kanemoto, Y., Tsunetoshi, Y., Ikebe, S., Yamamoto, K., Morishita, R., Shimazu, K., & Taniyama, Y. (2024). The Importance of Suppressing Pathological Periostin Splicing Variants with Exon 17 in Both Stroma and Cancer. Cells. https://doi.org/10.3390/cells13171410
Vancouver
Shibata K, Koibuchi N, Sanada F, Katsuragi N, Kanemoto Y, Tsunetoshi Y, et al. The Importance of Suppressing Pathological Periostin Splicing Variants with Exon 17 in Both Stroma and Cancer. Cells. 2024. doi:10.3390/cells13171410
BibTeX
@article{Shibata2024,
author = {Shibata, Kana and Koibuchi, Nobutaka and Sanada, Fumihiro and Katsuragi, Naruto and Kanemoto, Yuko and Tsunetoshi, Yasuo and Ikebe, Shoji and Yamamoto, Koichi and Morishita, Ryuichi and Shimazu, Kenzo and Taniyama, Yoshiaki},
title = {The Importance of Suppressing Pathological Periostin Splicing Variants with Exon 17 in Both Stroma and Cancer},
journal = {Cells},
year = {2024},
doi = {10.3390/cells13171410}
}
EUVIMED